Different effects of two α-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level
- 30 June 2004
- journal article
- research article
- Published by Elsevier BV in Journal of Diabetes and its Complications
- Vol. 18 (3), 183-186
- https://doi.org/10.1016/s1056-8727(03)00055-2
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Efficacy and Safety of Acarbose in Insulin-Treated Patients With Type 2 DiabetesDiabetes Care, 1998
- Effects of Voglibose on Glycemic Excursions, Insulin Secretion, and Insulin Sensitivity in Non-lnsulin-ireated NIDDM PatientsDiabetes Care, 1998
- Effect of acarbose on blood glucose profiles and plasma 1,5-anhydro-D-glucitol in type 2 diabetes poorly controlled by sulfonylurea therapyBiomedicine & Pharmacotherapy, 1996
- Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjectsMetabolism, 1996
- A new chemical diagnostic method for inborn errors of metabolism by mass spectrometry—rapid, practical, and simultaneous urinary metabolites analysisMass Spectrometry Reviews, 1996
- 1,5-Anhydro-D-glucitol Evaluates Daily Glycemic Excursions in Well-Controlled NIDDMDiabetes Care, 1995
- Efficacy of α‐glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemiaEuropean Journal of Clinical Investigation, 1994
- Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patientsDiabetologia, 1988
- The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in manZeitschrift für Die Gesamte Experimentelle Medizin, 1979
- Variation in polyol levels in cerebrospinal fluid and serum in diabetic patientsDiabetologia, 1975